Screening for glaucoma using eye photos, eye pressure and side vision tests
Tests a new glaucoma screening approach in adults with diabetic eye checks.
Plain-language title generated from the registry record
Registry title: The Glaucoma and Retinopathy Screening Study
Key facts
- Where
- Boston, Chelsea, Lynn, Salem, and Saugus, United StatesSee the 7 sites
Where in United States
- Brigham and Women's Primary Care Associates of LongwoodBoston, United StatesTaking people
- Massachusetts General Hospital Broadway Primary Care-RevereBoston, United StatesTaking people
- Massachusetts General Hospital Internal Medicine AssociatesBoston, United StatesTaking people
- MGH Chelsea HealthCare CenterChelsea, United StatesTaking people
- NSPG LynnLynn, United StatesTaking people
- NSPG SalemSalem, United StatesNot yet recruiting
- NSPG SaugusSaugus, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Massachusetts Eye and Ear Infirmary
- Trial code
- NCT06882356
- Record updated
- 27 August 2026
- Original description
The goal of this clinical trial is to learn if a new screening approach including an artificial intelligence algorithm that analyzes fundus photographs, measurement of eye pressure and visual field testing works to screen for glaucoma.Read full original descriptionShow less
The Glaucoma and Retinopathy Screening Study (GRaSS)
The goal of this clinical trial is to learn if a new screening approach including an artificial intelligence algorithm that analyzes fundus photographs, measurement of eye pressure and visual field testing works to screen for glaucoma.
Participants will:
Have an image of their fundus (back of the eye) taken as part of their diabetic eye screening Have a measurement of their eye pressure If needed, have a test of their side vision using a headset
Individuals with diabetes undergoing AI-based screening for diabetic retinopathy using the LumineticsCore (Digital Diagnostics) system at primary care centers; Individuals who are able and willing to provide informed consent for participation in the study.